Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …

This article aims to highlight the dosing issues of direct oral anticoagulants (DOACs) in
patients with renal impairment and/or obesity in an attempt to develop solutions employing …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Objective Through predictable pharmacokinetics—including a convenient fixed-dose
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Background: While commonly prescribed today, direct oral anticoagulants (DOACs) have
historically been avoided in patients with class III obesity or a weight> 120 kg due to limited …